

# Laurent Bertoletti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1539817/publications.pdf>

Version: 2024-02-01

231  
papers

7,011  
citations

94381

37  
h-index

71651

76  
g-index

295  
all docs

295  
docs citations

295  
times ranked

8315  
citing authors

#	ARTICLE	IF	CITATIONS
1	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017, 377, 1319-1330.	13.9	1,745
2	Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1536-1544.	1.2	258
3	Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2010, 35, 1286-1293.	3.1	226
4	Arterial and venous thromboembolism in COVID-19: a study-level meta-analysis. <i>Thorax</i> , 2021, 76, 970-979.	2.7	210
5	Pharmacological Agents Targeting Thromboinflammation in COVID-19: Review and Implications for Future Research. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1004-1024.	1.8	206
6	Pregnancy-Adapted YEARS Algorithm for Diagnosis of Suspected Pulmonary Embolism. <i>New England Journal of Medicine</i> , 2019, 380, 1139-1149.	13.9	200
7	Survival Effects of Inferior Vena Cava Filter in Patients With Acute Symptomatic Venous Thromboembolism and a Significant Bleeding Risk. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1675-1683.	1.2	167
8	Initial dual oral combination therapy in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2016, 47, 1727-1736.	3.1	124
9	Bronchoscopic Cryotherapy Treatment of Isolated Endoluminal Typical Carcinoid Tumor. <i>Chest</i> , 2006, 130, 1405-1411.	0.4	107
10	Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: A meta-analysis of observational studies. <i>Pharmacological Research</i> , 2017, 118, 19-32.	3.1	102
11	Association between Initial Treatment Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021, 204, 842-854.	2.5	94
12	Direct Oral Anticoagulants for the Treatment of Acute Venous Thromboembolism Associated with Cancer: A Systematic Review and Meta-Analysis. <i>Thrombosis and Haemostasis</i> , 2020, 120, 1128-1136.	1.8	93
13	Treatment and Long-Term Clinical Outcomes of Incidental Pulmonary Embolism in Patients With Cancer: An International Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2019, 37, 1713-1720.	0.8	90
14	The Clinical Course of Venous Thromboembolism May Differ According to Cancer Site. <i>American Journal of Medicine</i> , 2017, 130, 337-347.	0.6	83
15	Optimal follow-up after acute pulmonary embolism: a position paper of the European Society of Cardiology Working Group on Pulmonary Circulation and Right Ventricular Function, in collaboration with the European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology, endorsed by the European Respiratory Society. <i>European Heart Journal</i> , 2022, 43, 183-189.	1.0	83
16	Clinical presentation and outcome of venous thromboembolism in COPD. <i>European Respiratory Journal</i> , 2012, 39, 862-868.	3.1	80
17	Annual diagnosis rate of superficial vein thrombosis of the lower limbs: the STEPH community-based study. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 831-838.	1.9	77
18	Rivaroxaban vs Dalteparin in Cancer-Associated Thromboembolism. <i>Chest</i> , 2022, 161, 781-790.	0.4	75

#	ARTICLE	IF	CITATIONS
19	Echocardiography and pulmonary embolism severity index have independent prognostic roles in pulmonary embolism. <i>European Respiratory Journal</i> , 2013, 42, 681-688.	3.1	68
20	Pulmonary Hypertension in Patients With Neurofibromatosis Type I. <i>Medicine (United States)</i> , 2011, 90, 201-211.	0.4	60
21	A semi-mechanistic absorption model to evaluate drug-drug interaction with dabigatran: application with clarithromycin. <i>British Journal of Clinical Pharmacology</i> , 2013, 76, 107-113.	1.1	60
22	Accuracy and Feasibility of Electromagnetic Navigated Bronchoscopy under Nitrous Oxide Sedation for Pulmonary Peripheral Opacities: An Outpatient Study. <i>Respiration</i> , 2009, 78, 293-300.	1.2	56
23	Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized With Acutely Worsening Respiratory Symptoms. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 59.	3.8	52
24	Development of a Risk Prediction Score for Occult Cancer in Patients With VTE. <i>Chest</i> , 2017, 151, 564-571.	0.4	51
25	Multidetector-row CT angiography of renal artery stenosis in 50 consecutive patients: prospective interobserver comparison with DSA. <i>Radiologia Medica</i> , 2006, 111, 459-468.	4.7	48
26	Epidemiology, diagnosis, treatment and management of superficial-vein thrombosis of the legs. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 275-284.	0.7	48
27	Antiphospholipid antibodies can identify lupus patients at risk of pulmonary hypertension: A systematic review and meta-analysis. <i>Autoimmunity Reviews</i> , 2017, 16, 576-586.	2.5	48
28	Cancer-associated thrombosis in patients with implanted ports: a prospective multicenter French cohort study (ONCOICIP). <i>Blood</i> , 2018, 132, 707-716.	0.6	47
29	Venous thromboembolism in radiation therapy cancer patients: Findings from the RIETE registry. <i>Critical Reviews in Oncology/Hematology</i> , 2017, 113, 83-89.	2.0	45
30	Treatment of Right Heart Thrombi Associated with Acute Pulmonary Embolism. <i>American Journal of Medicine</i> , 2017, 130, 588-595.	0.6	45
31	Incomplete echocardiographic recovery at 6 months predicts long-term sequelae after intermediate-risk pulmonary embolism. A post-hoc analysis of the Pulmonary Embolism Thrombolysis (PEITHO) trial. <i>Clinical Research in Cardiology</i> , 2019, 108, 772-778.	1.5	44
32	Measuring functional limitations after venous thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale. <i>Thrombosis Research</i> , 2020, 190, 45-51.	0.8	44
33	Consistency of Safety and Efficacy of New Oral Anticoagulants across Subgroups of Patients with Atrial Fibrillation. <i>PLoS ONE</i> , 2014, 9, e91398.	1.1	43
34	Atrial fibrillation in cancer patients: Hindsight, insight and foresight. <i>International Journal of Cardiology</i> , 2017, 240, 196-202.	0.8	43
35	Risk factors for recurrent venous thromboembolism after unprovoked pulmonary embolism: the PADIS-PE randomised trial. <i>European Respiratory Journal</i> , 2018, 51, 1701202.	3.1	42
36	Pulmonary embolism and 3-month outcomes in 4036 patients with venous thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. <i>Respiratory Research</i> , 2013, 14, 75.	1.4	39

#	ARTICLE	IF	CITATIONS
37	Endobronchial Metastases from Colorectal Cancers: Natural History and Role of Interventional Bronchoscopy. <i>Respiration</i> , 2009, 77, 63-69.	1.2	38
38	Long-Term Anticoagulant Therapy of Patients with Venous Thromboembolism. What Are the Practices?. <i>PLoS ONE</i> , 2015, 10, e0128741.	1.1	38
39	Bleeding risk of terminally ill patients hospitalized in palliative care units: the RHESO study. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 420-428.	1.9	36
40	Noninvasive imaging of the coronary arteries using a 64-row multidetector CT scanner: initial clinical experience and radiation dose concerns. <i>Radiologia Medica</i> , 2007, 112, 31-46.	4.7	35
41	Individual patient data meta-analysis of enoxaparin vs. unfractionated heparin for venous thromboembolism prevention in medical patients. <i>Journal of Thrombosis and Haemostasis</i> , 2011, 9, 464-472.	1.9	35
42	Initial combination therapy of macitentan and tadalafil in pulmonary arterial hypertension. <i>European Respiratory Journal</i> , 2020, 56, 2000673.	3.1	35
43	Risk for Recurrent Venous Thromboembolism in Patients With Subsegmental Pulmonary Embolism Managed Without Anticoagulation. <i>Annals of Internal Medicine</i> , 2022, 175, 29-35.	2.0	33
44	MDCT of the abdominal aorta: basics, technical improvements, and clinical applications. <i>European Radiology</i> , 2003, 13, N53-N58.	2.3	32
45	Recent findings in the epidemiology, diagnosis and treatment of superficial-vein thrombosis. <i>Thrombosis Research</i> , 2011, 127, S81-S85.	0.8	32
46	In vitro and in vivo evaluation of drug-drug interaction between dabigatran and proton pump inhibitors. <i>Fundamental and Clinical Pharmacology</i> , 2015, 29, 604-614.	1.0	31
47	Outcomes Associated With Inferior Vena Cava Filters Among Patients With Thromboembolic Recurrence During Anticoagulant Therapy. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2440-2448.	1.1	31
48	Direct oral anticoagulants: Current indications and unmet needs in the treatment of venous thromboembolism. <i>Pharmacological Research</i> , 2017, 118, 33-42.	3.1	31
49	Early Use of Echocardiography in Patients With Acute Pulmonary Embolism: Findings From the RIETE Registry. <i>Journal of the American Heart Association</i> , 2018, 7, e009042.	1.6	31
50	Sex and gender in pulmonary arterial hypertension. <i>European Respiratory Review</i> , 2021, 30, 200330.	3.0	31
51	Spontaneous acute superficial vein thrombosis of the legs: do we really need to treat?. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, S230-S237.	1.9	30
52	Dosing issues with non-vitamin K antagonist oral anticoagulants for the treatment of non-valvular atrial fibrillation: Why we should not underdose our patients. <i>Archives of Cardiovascular Diseases</i> , 2018, 111, 85-94.	0.7	29
53	Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in Patients Hospitalized for COPD Exacerbation. <i>JAMA - Journal of the American Medical Association</i> , 2021, 326, 1277.	3.8	28
54	Effect of Activated Charcoal on Rivaroxaban Complex Absorption. <i>Clinical Pharmacokinetics</i> , 2017, 56, 793-801.	1.6	27

#	ARTICLE	IF	CITATIONS
55	Frequency and prognostic impact of acute kidney injury in patients with acute pulmonary embolism. Data from the RIETE registry. <i>International Journal of Cardiology</i> , 2019, 291, 121-126.	0.8	27
56	Consistency of safety profile of new oral anticoagulants in patients with renal failure. <i>Journal of Thrombosis and Haemostasis</i> , 2014, 12, 337-343.	1.9	26
57	Clinical outcomes during anticoagulant therapy in fragile patients with venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2017, 1, 172-179.	1.0	26
58	Extended Anticoagulation for VTE. <i>Chest</i> , 2019, 155, 1199-1216.	0.4	26
59	Hemodynamic Response to Treatment and Outcomes in Pulmonary Hypertension Associated With Interstitial Lung Disease Versus Pulmonary Arterial Hypertension in Systemic Sclerosis: Data From a Study Identifying Prognostic Factors in Pulmonary Hypertension Associated With Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 295-304.	2.9	26
60	Long-term treatment of venous thromboembolism with tinzaparin compared to vitamin K antagonists: A meta-analysis of 5 randomized trials in non-cancer and cancer patients. <i>Thrombosis Research</i> , 2012, 130, 853-858.	0.8	25
61	Extended anticoagulation for the secondary prevention of venous thromboembolic events: An updated network meta-analysis. <i>PLoS ONE</i> , 2019, 14, e0214134.	1.1	25
62	Factor XI Inhibition for the Prevention of Venous Thromboembolism: An Update on Current Evidence and Future perspectives. <i>Vascular Health and Risk Management</i> , 0, Volume 18, 359-373.	1.0	25
63	Effects of impaired renal function on levels and performance of D-dimer in patients with suspected pulmonary embolism. <i>Thrombosis and Haemostasis</i> , 2014, 112, 614-620.	1.8	23
64	DVT Management and Outcome Trends, 2001 to 2014. <i>Chest</i> , 2016, 150, 374-383.	0.4	23
65	Genesis of an emergency public drug information website by the French Society of Pharmacology and Therapeutics during the COVID-19 pandemic. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 389-396.	1.0	23
66	DOAC compared to LMWH in the treatment of cancer related-venous thromboembolism: a systematic review and meta-analysis. <i>Journal of Thrombosis and Thrombolysis</i> , 2020, 50, 661-667.	1.0	23
67	Acute venous thromboembolism after non-major orthopaedic surgery or post-traumatic limb immobilisation. <i>Thrombosis and Haemostasis</i> , 2011, 105, 739-741.	1.8	22
68	Predicting the risk of cancer after unprovoked venous thromboembolism: external validation of the RIETE score. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 2184-2187.	1.9	22
69	Early detection of the existence or absence of the treatment effect: A cumulative meta-analysis. <i>Journal of Clinical Epidemiology</i> , 2020, 124, 24-33.	2.4	22
70	Predictors of Post-Thrombotic Ulcer after Acute DVT: The RIETE Registry. <i>Thrombosis and Haemostasis</i> , 2018, 118, 320-328.	1.8	21
71	In Vitro Assessment of Pharmacokinetic Drug-Drug Interactions of Direct Oral Anticoagulants: Type 5-Phosphodiesterase Inhibitors Are Inhibitors of Rivaroxaban and Apixaban Efflux by P-Glycoprotein. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018, 365, 519-525.	1.3	21
72	Pulmonary embolism: Epidemiology and registries. <i>Presse Medicale</i> , 2015, 44, e377-e383.	0.8	20

#	ARTICLE	IF	CITATIONS
73	Benefit of Risk Score-Guided Prophylaxis in Pregnant Women at Risk of Thrombotic Events: A Controlled Before-and-After Implementation Study. <i>Thrombosis and Haemostasis</i> , 2018, 118, 1564-1571.	1.8	20
74	Infection as cause of immobility and occurrence of venous thromboembolism: analysis of 1635 medical cases from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 404-412.	1.0	19
75	Long-Term Treatment of Cancer-Associated Thrombosis (CAT) Beyond 6 Months in the Medical Practice: USCAT, a 432-Patient Retrospective Non-Interventional Study. <i>Cancers</i> , 2020, 12, 2256.	1.7	19
76	Risk of Direct Oral Anticoagulant Bioaccumulation in Patients with Pulmonary Hypertension. <i>Respiration</i> , 2016, 91, 307-315.	1.2	18
77	Lived experience of having a child with stroke: A qualitative study. <i>European Journal of Paediatric Neurology</i> , 2017, 21, 542-548.	0.7	18
78	In vitro assessment of P-gp and BCRP transporter-mediated drug-drug interactions of riociguat with direct oral anticoagulants. <i>Fundamental and Clinical Pharmacology</i> , 2020, 34, 109-119.	1.0	18
79	Severe renal impairment and risk of bleeding during anticoagulation for venous thromboembolism. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 1728-1737.	1.9	18
80	Direct oral anticoagulant use in patients with thrombophilia, antiphospholipid syndrome or venous thrombosis of unusual sites: A narrative review. <i>Blood Reviews</i> , 2018, 32, 272-279.	2.8	17
81	Predictors for Residual Pulmonary Vascular Obstruction after Unprovoked Pulmonary Embolism: Implications for Clinical Practice—The PADIS-PE Trial. <i>Thrombosis and Haemostasis</i> , 2019, 119, 1489-1497.	1.8	17
82	Twice- or Once-Daily Dosing of Direct Oral Anticoagulants, a systematic review and meta-analysis. <i>Thrombosis Research</i> , 2021, 197, 24-32.	0.8	17
83	Obstructive Sleep Apnea, Hypercoagulability, and the Blood-Brain Barrier. <i>Journal of Clinical Medicine</i> , 2021, 10, 3099.	1.0	17
84	Indications and potential pitfalls of anticoagulants in pulmonary hypertension: Would DOACs become a better option than VKAs?. <i>Blood Reviews</i> , 2019, 37, 100579.	2.8	16
85	Prognostic value of the Geneva prediction rule in patients with pulmonary embolism. <i>Thrombosis Research</i> , 2013, 132, 32-36.	0.8	15
86	Impact of double-blind vs. open study design on the observed treatment effects of new oral anticoagulants in atrial fibrillation: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2013, 11, 1240-1250.	1.9	15
87	Vitamin K Antagonists After 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. <i>American Journal of Medicine</i> , 2018, 131, 430-437.	0.6	15
88	Definition of bleeding events in studies evaluating prophylactic antithrombotic therapy in pregnant women: A systematic review and a proposal from the ISTH SSC. <i>Journal of Thrombosis and Haemostasis</i> , 2019, 17, 1979-1988.	1.9	15
89	What's next after the clot? Residual pulmonary vascular obstruction after pulmonary embolism: From imaging finding to clinical consequences. <i>Thrombosis Research</i> , 2019, 184, 67-76.	0.8	15
90	Use of Anticoagulants in Patients with Pulmonary Hypertension. <i>Hamostaseologie</i> , 2020, 40, 348-355.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Direct oral anticoagulants in the treatment of acute venous thromboembolism in patients with obesity: A systematic review with meta-analysis. <i>Pharmacological Research</i> , 2021, 163, 105317.	3.1	15
92	Clinical Presentation and Short- and Long-term Outcomes in Patients With Isolated Distal Deep Vein Thrombosis vs Proximal Deep Vein Thrombosis in the RIETE Registry. <i>JAMA Cardiology</i> , 2022, 7, 857.	3.0	15
93	Value of a Planned Compression Ultrasonography after an Isolated Superficial Vein Thrombosis: Results from a Prospective Multicentre Study. <i>European Journal of Vascular and Endovascular Surgery</i> , 2012, 43, 233-237.	0.8	14
94	Statistical controversies in clinical research: limitations of open-label studies assessing antiangiogenic therapies with regard to evaluation of vascular adverse drug events—a meta-analysis. <i>Annals of Oncology</i> , 2018, 29, 803-811.	0.6	14
95	Autonomic cardiovascular adaptations to acute head-out water immersion, head-down tilt and supine position. <i>European Journal of Applied Physiology</i> , 2020, 120, 337-347.	1.2	14
96	Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism. <i>Chest</i> , 2022, 161, 524-534.	0.4	14
97	Renal function and clinical outcome of patients with cancer-associated venous thromboembolism randomized to receive apixaban or dalteparin. Results from the Caravaggio trial. <i>Haematologica</i> , 2022, 107, 1567-1576.	1.7	14
98	Volumetric evaluation of therapy response in patients with lung metastases. Preliminary results with a computer system (CAD) and comparison with unidimensional measurements. <i>Radiologia Medica</i> , 2006, 111, 365-375.	4.7	13
99	Rate and duration of hospitalisation for acute pulmonary embolism in the real-world clinical practice of different countries: analysis from the RIETE registry. <i>European Respiratory Journal</i> , 2019, 53, 1801677.	3.1	13
100	Renal dysfunction improves risk stratification and may call for a change in the management of intermediate- and high-risk acute pulmonary embolism: results from a multicenter cohort study with external validation. <i>Critical Care</i> , 2021, 25, 57.	2.5	13
101	Effectiveness and Safety of Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism: A Nationwide Comparative Cohort Study in France. <i>Thrombosis and Haemostasis</i> , 2022, 122, 1384-1396.	1.8	13
102	Venous thromboembolism and radiation therapy: The final <sc>radiation-induced</sc> thrombosis study analysis. <i>Cancer Medicine</i> , 2022, 11, 1753-1762.	1.3	13
103	Recurrence of venous thromboembolism in patients with recent gestational deep vein thrombosis or pulmonary embolism: Findings from the RIETE Registry. <i>European Journal of Internal Medicine</i> , 2016, 32, 53-59.	1.0	12
104	Phenotype and Outcomes of Pulmonary Hypertension Associated with Neurofibromatosis Type 1. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020, 202, 843-852.	2.5	12
105	Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 408-416.	1.9	12
106	Factors Associated with elevated Pulmonary Arterial Pressure Levels on the Echocardiographic Assessment in Patients with Prior Pulmonary Embolism. <i>Thrombosis Research</i> , 2013, 131, e191-e195.	0.8	11
107	Assessment of clinically relevant bleeding as a surrogate outcome for major bleeding: validation by meta-analysis of randomized controlled trials. <i>Journal of Thrombosis and Haemostasis</i> , 2017, 15, 1547-1558.	1.9	11
108	Evaluation of the predictive value of the bleeding prediction score VTE-BLEED for recurrent venous thromboembolism. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2019, 3, 364-371.	1.0	11

#	ARTICLE	IF	CITATIONS
109	Early switch to oral anticoagulation in patients with acute intermediate-risk pulmonary embolism (PEITHO-2): a multinational, multicentre, single-arm, phase 4 trial. <i>Lancet Haematology</i> , 2021, 8, e627-e636.	2.2	11
110	Dabigatran Level Before Reversal Can Predict Hemostatic Effectiveness of Idarucizumab in a Real-World Setting. <i>Frontiers in Medicine</i> , 2020, 7, 599626.	1.2	11
111	Antithrombotics in pulmonary hypertension: more work needed before we turn to newer agents!. <i>European Respiratory Journal</i> , 2013, 41, 775-777.	3.1	10
112	Indirect comparison meta-analysis of two enoxaparin regimens in patients undergoing major orthopaedic surgery. <i>Thrombosis and Haemostasis</i> , 2014, 112, 503-510.	1.8	10
113	Venous thromboembolism and COVID-19. <i>Respiratory Medicine and Research</i> , 2020, 78, 100759.	0.4	10
114	Symptomatic subsegmental versus more central pulmonary embolism: Clinical outcomes during anticoagulation. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 168-178.	1.0	10
115	Thromboembolic events following brachytherapy:. <i>Journal of Contemporary Brachytherapy</i> , 2015, 1, 76-78.	0.4	9
116	A Prognostic Score to Identify Low-risk Outpatients with Acute Deep Vein Thrombosis in the Lower Limbs. <i>American Journal of Medicine</i> , 2015, 128, 90.e9-90.e15.	0.6	9
117	Areas of improvement in anticoagulant safety. Data from the CACAO study, a cohort in general practice. <i>PLoS ONE</i> , 2017, 12, e0175167.	1.1	9
118	The rationale, design, and methods of a randomized, controlled trial to evaluate the efficacy and safety of an active strategy for the diagnosis and treatment of acute pulmonary embolism during exacerbations of chronic obstructive pulmonary disease. <i>Clinical Cardiology</i> , 2019, 42, 346-351.	0.7	9
119	Direct oral anticoagulants for venous thromboembolism prophylaxis in critically ill patients: where do we go from here?. <i>Intensive Care Medicine</i> , 2019, 45, 549-551.	3.9	9
120	Cardiovascular disease events within 5 years after a diagnosis of breast cancer. <i>BMC Cancer</i> , 2020, 20, 337.	1.1	9
121	A prognostic score to identify low-risk outpatients with acute deep vein thrombosis in the upper extremity. <i>Journal of Thrombosis and Haemostasis</i> , 2015, 13, 1274-1278.	1.9	8
122	Evaluation of Venous Thromboembolism Recurrence Scores in an Unprovoked Pulmonary Embolism Population: A Post-hoc Analysis of the PADIS-PE trial. <i>American Journal of Medicine</i> , 2020, 133, e406-e421.	0.6	8
123	Patient-Level, Institutional, and Temporal Variations in Use of Imaging Modalities to Confirm Pulmonary Embolism. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010651.	1.3	8
124	Anticoagulants™ Safety and Effectiveness in General Practice: A Nationwide Prospective Cohort Study. <i>Annals of Family Medicine</i> , 2020, 18, 131-138.	0.9	8
125	Right ventricle dysfunction in patients with acute pulmonary embolism supposedly at low risk for death: when evidence-based medicine rescues clinical practice. <i>European Heart Journal</i> , 2021, 42, 3200-3202.	1.0	8
126	Association between Leflunomide and Pulmonary Hypertension. <i>Annals of the American Thoracic Society</i> , 2021, 18, 1306-1315.	1.5	8



#	ARTICLE	IF	CITATIONS
127	Letter by Bertolletti et al Regarding Article, "Anticoagulation and Survival in Pulmonary Arterial Hypertension: Results From the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERRA)". <i>Circulation</i> , 2014, 130, e108.	1.6	7
128	Seasonal variation in the superficial vein thrombosis frequency. <i>Thrombosis Research</i> , 2015, 136, 1116-1119.	0.8	7
129	Role of a clinical prediction score in a chronic thromboembolic pulmonary hypertension rule-out strategy. <i>European Respiratory Journal</i> , 2018, 51, 1702576.	3.1	7
130	Compared to randomized studies, observational studies may overestimate the effectiveness of DOACs: a metaepidemiological approach. <i>Journal of Clinical Epidemiology</i> , 2021, 130, 49-58.	2.4	7
131	Recovery from acute kidney injury in patients with pulmonary embolism: A single-center study. <i>Thrombosis Research</i> , 2021, 199, 106-109.	0.8	7
132	Thromboprophylaxis strategies to improve the prognosis of COVID-19. <i>Vascular Pharmacology</i> , 2021, 139, 106883.	1.0	7
133	The prognostic value of respiratory symptoms and performance status in ambulatory cancer patients and unsuspected pulmonary embolism; analysis of an international, prospective, observational cohort study. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2791-2800.	1.9	7
134	Time course response after single injection of botulinum toxin to treat spasticity after stroke: Systematic review with pharmacodynamic model-based meta-analysis. <i>Annals of Physical and Rehabilitation Medicine</i> , 2022, 65, 101579.	1.1	7
135	Tyrosine kinase inhibitors and direct oral anticoagulants: In vitro evaluation of drug-drug interaction mediated by P-glycoprotein. <i>Fundamental and Clinical Pharmacology</i> , 2022, 36, 860-868.	1.0	7
136	Major gastrointestinal bleeding in patients receiving anticoagulant therapy for venous thromboembolism. <i>Thrombosis Research</i> , 2022, 214, 29-36.	0.8	7
137	Adequate use of pulmonary embolism clinical prediction rule in COPD patients. <i>European Respiratory Journal</i> , 2011, 37, 219-220.	3.1	6
138	Ventilation/perfusion (V/Q) scanning in contemporary patients with pulmonary embolism: utilization rates and predictors of use in a multinational study. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 829-840.	1.0	6
139	Enoxaparin versus dalteparin or tinzaparin in patients with cancer and venous thromboembolism: The RIETECAT study. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2022, 6, e12736.	1.0	6
140	MDCT assessment of lung volume in patients undergoing bronchial stenting for treatment of pulmonary emphysema: correlation with respiratory tests and personal experience. <i>Radiologia Medica</i> , 2006, 111, 749-758.	4.7	5
141	Prior thromboprophylaxis and outcome in patients experiencing acute venous thromboembolism after an acute medical illness. <i>European Journal of Internal Medicine</i> , 2016, 30, 72-76.	1.0	5
142	The paradoxical association between pulmonary embolism and COPD. <i>European Respiratory Journal</i> , 2017, 50, 1700959.	3.1	5
143	Outcomes following a negative computed tomography pulmonary angiography according to pulmonary embolism prevalence: a meta-analysis of the management outcome studies. <i>Journal of Thrombosis and Haemostasis</i> , 2018, 16, 1107-1120.	1.9	5
144	The Ottawa score performs poorly in cancer patients with incidental pulmonary embolism. <i>Thrombosis Research</i> , 2019, 181, 59-63.	0.8	5

#	ARTICLE	IF	CITATIONS
145	COPD is not only one of the several VTE risk factors. <i>European Journal of Internal Medicine</i> , 2021, 84, 14-15.	1.0	5
146	OC-15 Risk factors of recurrence in cancer-associated venous thromboembolism after discontinuation of anticoagulant therapy: a RIETE-based prospective study. <i>Thrombosis Research</i> , 2021, 200, S15.	0.8	5
147	Cardiac Biomarkers in Patients with Acute Pulmonary Embolism. <i>Medicina (Lithuania)</i> , 2022, 58, 541.	0.8	5
148	Is tidal expiratory flow limitation predictive of sleep-related disorders in the elderly?. <i>European Respiratory Journal</i> , 2010, 36, 842-848.	3.1	4
149	Prognostic value of the Geneva prediction rule in patients in whom pulmonary embolism is ruled out. <i>Journal of Internal Medicine</i> , 2011, 269, 433-440.	2.7	4
150	Should We Screen for Pulmonary Hypertension at the Initial Evaluation of Idiopathic Pulmonary Fibrosis?. <i>Respiration</i> , 2013, 85, 452-455.	1.2	4
151	Connective tissue disease associated with pulmonary arterial hypertension: management of a patient with severe haemodynamic impairment. <i>European Respiratory Review</i> , 2014, 23, 505-509.	3.0	4
152	Secondary Prevention of Childhood Arterial Ischemic Stroke. <i>Journal of Child Neurology</i> , 2017, 32, 488-493.	0.7	4
153	Practical issues in suspected venous thrombosis in general practice: A multicentre prospective cohort in primary care. <i>Thrombosis Research</i> , 2017, 158, 19-21.	0.8	4
154	Cancer incidence in patients with pre-capillary pulmonary hypertension. <i>Journal of Heart and Lung Transplantation</i> , 2019, 38, 778-780.	0.3	4
155	Management of isolated distal deep vein thrombosis with direct oral anticoagulants in the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 532-541.	1.0	4
156	Chronic thromboembolic pulmonary hypertension complicating long-term cyproterone acetate therapy. <i>European Respiratory Review</i> , 2014, 23, 260-263.	3.0	3
157	Pronóstico de la enfermedad tromboembólica venosa en cirugía ortopédica o pacientes traumatológicos y uso de tromboprofilaxis. <i>Revista Clínica Española</i> , 2018, 218, 399-407.	0.2	3
158	Chronic thromboembolic pulmonary hypertension suspicion after pulmonary embolism in cancer patients. <i>Respiratory Medicine and Research</i> , 2019, 76, 34-37.	0.4	3
159	Ruling out deep vein thrombosis in patients with superficial vein thrombosis: external validation of the ICARO score. <i>Journal of Thrombosis and Thrombolysis</i> , 2019, 47, 96-101.	1.0	3
160	Prognostic impact of acute kidney injury in patients with acute pulmonary embolism data from the RIETE registry. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 54, 58-66.	1.0	3
161	Sex Differences in Presentation, Risk Factors, Drug and Interventional Therapies, and Outcomes of Elderly Patients with Pulmonary Embolism: Rationale and design of the SERIOUS-PE study. <i>Thrombosis Research</i> , 2022, 214, 122-131.	0.8	3
162	The cloud of pulmonary embolism during COPD exacerbation. <i>Thorax</i> , 2012, 67, 177.3-178.	2.7	2

#	ARTICLE	IF	CITATIONS
163	PK evaluation of fondaparinux sodium for the treatment of thrombosis. Expert Opinion on Drug Metabolism and Toxicology, 2014, 10, 269-277.	1.5	2
164	Successful retrieval of a long-lasting temporary inferior vena cava filter. Diagnostic and Interventional Imaging, 2016, 97, 481-482.	1.8	2
165	Evaluation of direct oral anticoagulants in superficial-vein thrombosis. Lancet Haematology, the, 2017, 4, e254.	2.2	2
166	“Rehab for all” is it too early in pulmonary arterial hypertension?. European Respiratory Journal, 2019, 54, 1901558.	3.1	2
167	Reasons Influencing Long-Term Anticoagulant Treatment Beyond 6 Months for Cancer-Associated Thrombosis in USCAT, A 432-Patient Retrospective Non-Interventional Study. Journal of Cancer Science and Clinical Therapeutics, 2021, 05, .	0.2	2
168	Management of superficial venous thrombosis in unevaluated situations: Cancer, severe renal impairment, pregnancy and post-partum. Phlebology, 2021, 36, 464-472.	0.6	2
169	Pulmonary Embolism Prevalence Among Hospitalized Patients With COPD—Reply. JAMA - Journal of the American Medical Association, 2021, 325, 1903.	3.8	2
170	Imaging modalities for confirming pulmonary embolism during pregnancy: results from a multicenter international study. European Radiology, 2022, 32, 1238-1246.	2.3	2
171	Management of acute venous thromboembolism in patients taking antiplatelet therapy. Thrombosis Research, 2021, 208, 156-161.	0.8	2
172	The impact of advanced age on anticoagulant therapy for acute venous thromboembolism. Expert Opinion on Drug Metabolism and Toxicology, 2022, 18, 27-37.	1.5	2
173	Cardiovascular Diseases Following Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2022, 45, 155-160.	0.6	2
174	PO-41: Cancer-associated thrombosis: how many patients seen in clinical practice would be eligible to a randomized controlled trial?. Thrombosis Research, 2022, 213, S30.	0.8	2
175	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. ERJ Open Research, 2022, 8, 00665-2021.	1.1	2
176	Trends in Cause-Specific Mortality in Oxygen-dependent COPD: What about Pulmonary Embolism?. American Journal of Respiratory and Critical Care Medicine, 2011, 184, 1211-1212.	2.5	1
177	Pulmonary embolism: An update. Presse Medicale, 2015, 44, e373-e376.	0.8	1
178	Prognosis of venous thromboembolism in orthopaedic surgery or trauma patients and use of thromboprophylaxis. Revista Clínica Española, 2018, 218, 399-407.	0.3	1
179	Avoiding disease mongering: A checklist for vascular physicians and researchers. Thrombosis Research, 2019, 181, 120-123.	0.8	1
180	Unresolved questions on venous thromboembolic disease. Consensus statement of the French Society for Vascular Medicine (SFMV). JMV-Journal De Medecine Vasculaire, 2019, 44, 28-70.	0.1	1

#	ARTICLE	IF	CITATIONS
181	Pulmonary hypertension due to pulmonary artery obstructions by malignant tumoral cells. <i>Respiratory Medicine and Research</i> , 2019, 76, 10-12.	0.4	1
182	Radiation optic neuropathy and stroke suspicion. <i>JMV-Journal De Medecine Vasculaire</i> , 2020, 45, 232-233.	0.1	1
183	How can we better predict pulmonary blood clots in patients hospitalised for COVID-19?. <i>European Respiratory Journal</i> , 2020, 56, 2003092.	3.1	1
184	Direct oral anticoagulants: Still too early for prime time after pulmonary endarterectomy?. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 758-759.	1.9	1
185	Meta-regression of randomized control trials with antithrombotics: weak correlation between net clinical benefit and all cause-mortality. <i>Scientific Reports</i> , 2021, 11, 14728.	1.6	1
186	How many patients recover from acute kidney injury after pulmonary embolism?. , 2020, , .		1
187	Initial Anticoagulant Treatment of Pulmonary Embolism. <i>Chest</i> , 2021, 160, 1596-1598.	0.4	1
188	Frequency and risk factors for Chronic Thromboembolic Pulmonary Hypertension after a first unprovoked Pulmonary Embolism: results from PADIS-studies. , 2021, , .		1
189	Treatment of Portal, Mesenteric, and Splenic Vein Thrombosis with Rivaroxaban: A Pilot, Prospective Cohort Study. <i>Blood</i> , 2021, 138, 671-671.	0.6	1
190	Can Medicine be Compared with Art?. <i>Southern Medical Journal</i> , 2008, 101, 469.	0.3	0
191	R�ponse � la lettre � la r�daction soumise par le Dr R�my Boussageon (d�partement de m�decine) Tj ETQq1 1 0.784314 BLA dans lâ€™asthme est-elle si peu d�velopp�e�. <i>Revue Des Maladies Respiratoires</i> , 2011, 28, 1080-1081.	1.7	0
192	PO-0753: Radiation therapy and outcome in cancer patients with acute venous thromboembolism. <i>Radiotherapy and Oncology</i> , 2017, 123, S397.	0.3	0
193	Chronic thromboembolic pulmonary hypertension in cancer patients with pulmonary embolism. <i>Thrombosis Research</i> , 2018, 164, S209-S210.	0.8	0
194	In patients with cancer, prognostic factors of catheter-related thrombosis (CRT) are different than prognostic factors of VTE. A prospective cohort study in 3032 cancer patients with central venous catheter (ONCOCIP). <i>Thrombosis Research</i> , 2018, 164, S216-S217.	0.8	0
195	Screening cancer after venous thromboembolism: How many abnormal tests before diagnosing cancer? An analysis of practice. <i>Presse Medicale</i> , 2018, 47, e99-e106.	0.8	0
196	Treatment and long-term clinical outcomes of incidental pulmonary embolism in cancer patients: an international prospective cohort study. <i>Thrombosis Research</i> , 2018, 164, S193-S194.	0.8	0
197	Implementation of a systematic comprehensive geriatric assessment for elderly patients suspected of pulmonary hypertension. <i>Respiratory Medicine and Research</i> , 2020, 78, 100785.	0.4	0
198	DOAC Compared to LMWH in the Treatment of Cancer Related-Venous Thromboembolism: A Systematic Review and Meta-Analysis. , 2020, , .		0

#	ARTICLE	IF	CITATIONS
199	First three months of anticoagulation for venous thromboembolism in non-cancer patients: LMWH VS. VKAs. Findings from the RIETE registry. <i>Thrombosis Update</i> , 2020, 1, 100010.	0.4	0
200	DLNO/DLCO ratio evolution under targeted therapy in patients with pulmonary hypertension. <i>Respiratory Physiology and Neurobiology</i> , 2020, 279, 103467.	0.7	0
201	PO-46 Incident cardiovascular events after diagnosis of breast cancer: a cohort study in 682 patients. <i>Thrombosis Research</i> , 2021, 200, S41-S42.	0.8	0
202	PO-39 Superficial venous thrombosis in patients with active cancer: characteristics and management. <i>Thrombosis Research</i> , 2021, 200, S37-S38.	0.8	0
203	OC-17 Rivaroxaban versus Dalteparin for the Treatment of Cancer-Associated Venous Thromboembolism: the CASTA DIVA Trial. <i>Thrombosis Research</i> , 2021, 200, S16.	0.8	0
204	Anticancer drugs associated with venous thromboembolic event: Analysis of the WHO pharmacovigilance database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3094-3094.	0.8	0
205	Breast cancer treatment-related cardiovascular disturbances: advocacy for a watchful attitude in this never-ending story. <i>Expert Opinion on Drug Safety</i> , 2021, , 1-13.	1.0	0
206	RIETE: Past and future. <i>JMV-Journal De Medecine Vasculaire</i> , 2021, 46, S1.	0.1	0
207	Effectiveness and safety of oral anticoagulants in the treatment of acute venous thromboembolism: a comparative cohort study in France. <i>European Heart Journal</i> , 2021, 42, .	1.0	0
208	Never Forget the "Priceless" Diagnosis!. <i>Southern Medical Journal</i> , 2009, 102, 997-998.	0.3	0
209	Pulmonary hypertension in orphan lung diseases. , 2011, , 317-331.		0
210	Initial dual oral combination therapy for pulmonary arterial hypertension (PAH) in daily practice. , 2015, , .		0
211	Evolution of pulmonary blood volume under anticoagulant therapy after a first symptomatic pulmonary embolism. , 2015, , .		0
212	Risk Factors for Venous Ulcer Following ACUTE Venous Thromboembolism: Results from the Riete Registry. <i>Blood</i> , 2015, 126, 3548-3548.	0.6	0
213	After deep vein thrombosis, which patients refer to vascular specialist for anticoagulant withdrawal? A Delphi study results between general practitioners and vascular specialists. <i>Presse Medicale</i> , 2017, 46, e77-e83.	0.8	0
214	Hemorrhagic and thrombotic events in oncology patients treated with antiangiogenic therapy: Impact of study design on the results assessed by meta-analysis.. <i>Journal of Clinical Oncology</i> , 2017, 35, e14058-e14058.	0.8	0
215	Impact of patients'™ setting on the prevalence of pulmonary embolism in acute exacerbation of COPD: a meta-analysis of observational studies. , 2017, , .		0
216	Evolution of DLNO/DLCO ratio after initiation of targeted PH therapy in naïve patients. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
217	Cancer incidence in incident patients with precapillary pulmonary hypertension.. , 2018, , .		0
218	Pulmonary hypertension in patients with idiopathic pulmonary fibrosis and combined pulmonary fibrosis and emphysema: hemodynamic severity. , 2018, , .		0
219	Frequency of chronic thromboembolic pulmonary hypertension screening after pulmonary embolism in cancer patients.. , 2018, , .		0
220	Follow-up of guidelines and impact on the management of suspected deep vein thrombosis in emergency departments. JMV-Journal De Medecine Vasculaire, 2020, 45, 326-333.	0.1	0
221	RIETE: Past and future. JMV-Journal De Medecine Vasculaire, 2020, 45, S1.	0.1	0
222	Association between Leflunomide and Pulmonary Hypertension. , 2021, , .		0
223	Prognostic impact of acute kidney injury in patients with acute pulmonary embolism.Data from the RIETE registry. , 2021, , .		0
224	Anticoagulant Treatment Patterns and Outcomes in Patients with Venous Thromboembolism and Active Cancer - a Nationwide Cohort Study in France. Blood, 2021, 138, 670-670.	0.6	0
225	Implementation of a systematic comprehensive geriatric assessment for elderly patients suspected of pulmonary hypertension. , 2020, , .		0
226	Long-term outcomes in incident pulmonary arterial hypertension (PAH) patients initiated with triple combination therapy including parenteral prostacyclin (PGI2). , 2020, , .		0
227	Adherence to guidelines of anticoagulant prescription in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: an observational study. , 2020, , .		0
228	Renal function improves mortality prediction in acute pulmonary embolism: results of a multicentre cohort study with external validation in the RIETE registry. European Heart Journal, 2020, 41, .	1.0	0
229	Abstract 14569: Direct Oral Anticoagulants in the Treatment of Acute Venous Thromboembolism in Obese Patients: A Systematic Review With Meta-analysis. Circulation, 2020, 142, .	1.6	0
230	Abstract 14699: Arterial and Venous Thromboembolism in Covid-19: A Study-level Meta-analysis. Circulation, 2020, 142, .	1.6	0
231	TEMPORARY REMOVAL: PO-55: Effectiveness and safety of enoxaparin in the extended treatment of venous thromboembolism in active cancer patients with renal impairment: results from the RIETECAT-RI cohort study. Thrombosis Research, 2022, 213, S37-S38.	0.8	0